Amphastar Q1 2022 revenue $120.4M (+17% YoY); GAAP EPS $0.47 vs $0.10

Amphastar Pharmaceuticals, Inc.

2022-Q1 EPS reported $0.47 revenue$120,368,000

Net revenues $120.4M for Q1 2022, up from $103.0M in Q1 2021 (+17% YoY).
GAAP net income $24.3M ($0.47 diluted EPS) vs $5.0M ($0.10) a year ago.
Adjusted non-GAAP net income $24.6M ($0.47 EPS) vs $13.6M ($0.27) in Q1 2021.
CEO cites strong sales of recent complex product launches; optimistic for continued growth.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.